Dennis P. Schafer
Keine laufenden Positionen mehr
Profil
Dennis P.
Schafer was the founder and had founded Curry Pharmaceuticals Corp.
in 2003, where he held the title of President & Chief Executive Officer.
He has also held former positions as President, Chief Executive Officer & Director at Altheus Therapeutics, Inc., President & Chief Executive Officer at Accuronix Therapeutics, Inc., Director at FASgen, Inc., Director at FASgen LLC, President at ADERIS Pharmaceuticals, Inc., President at Secretech, Inc., Venture Partner at Academy Ventures LLC, and Chief Operating Officer at Somatocor Pharmaceuticals, Inc. Mr. Schafer received his undergraduate degree from the University of Nebraska and his graduate degree, including an MBA, from the University of Virginia.
Ehemalige bekannte Positionen von Dennis P. Schafer
| Unternehmen | Position | Ende |
|---|---|---|
FASgen, Inc.
 FASgen, Inc. Pharmaceuticals: MajorHealth Technology FASgen, Inc. develops novel molecule therapeutics. It provides therapeutic applications for cancer, infectious diseases, and metabolic disorders including obesity and diabetes. The company was founded by James D. Dick, Frank P. Kuhajda, Albert H. Owens, and Craig A. Townsend in 2000 and is headquartered in Baltimore, MD. | Direktor/Vorstandsmitglied | 19.06.2012 |
Academy Ventures LLC
 Academy Ventures LLC Investment ManagersFinance Academy Funds is a family of venture capital funds located in Durham, North Carolina with an additional office in Greenville, South Carolina | Private Equity Investor | 31.12.2007 |
Accuronix Therapeutics, Inc.
 Accuronix Therapeutics, Inc. Medical SpecialtiesHealth Technology Accuronix Therapeutics, Inc. develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk. The firm also develops new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. Its s-2 receptors are expressed on the surface of rapidly proliferating cancer cells. The company was founded by William Hawkins and Robert Mach and is headquartered in St. Louis, MO. | Vorstandsvorsitzender | - |
Altheus Therapeutics, Inc.
 Altheus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Altheus Therapeutics, Inc. developed novel therapies for inflammatory bowel diseases. It developed Zoenasa oral tablets and rectal gel formulations as novel front-line therapies for the treatment of ulcerative colitis and other inflammatory bowel diseases. The company was founded by William A. Hagstrom and Richard F. Harty in 2006 and was headquartered Oklahoma, OK. | Vorstandsvorsitzender | - |
FASgen LLC
 FASgen LLC Pharmaceuticals: MajorHealth Technology FASgen LLC was engaged in pharmaceutical preparations. Its products are FAS-detect IHC and FAS-detect ELISA. The company was founded by Albert H. Owens Jr., Craig A. Townsend, James D. Dick and in 1999 and was headquartered in Baltimore, MD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Dennis P. Schafer
| University of Nebraska | Undergraduate Degree |
| University of Virginia | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
ADERIS Pharmaceuticals, Inc.
 ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA. | Health Technology |
Curry Pharmaceuticals Corp.
 Curry Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Curry Pharmaceuticals Corp. develops pharmaceutical products. It offers novel drugs for cancer, oncology, dermatology and other inflammatory diseases based on the natural product curcumin. The company was founded in 2003 by Dennis P. Schafer, Lowell A. Goldsmith, and Bharat Aggarwal and is headquartered in Durham, NC. | Health Technology |
Altheus Therapeutics, Inc.
Altheus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Altheus Therapeutics, Inc. developed novel therapies for inflammatory bowel diseases. It developed Zoenasa oral tablets and rectal gel formulations as novel front-line therapies for the treatment of ulcerative colitis and other inflammatory bowel diseases. The company was founded by William A. Hagstrom and Richard F. Harty in 2006 and was headquartered Oklahoma, OK. | Commercial Services |
Secretech, Inc.
 Secretech, Inc. Pharmaceuticals: MajorHealth Technology Secretech, Inc. is an American company that develops oral vaccines. Secretech was acquired by Zynaxis, Inc. on July 27, 1995 for $4.14 million. | Health Technology |
Academy Ventures LLC
Academy Ventures LLC Investment ManagersFinance Academy Funds is a family of venture capital funds located in Durham, North Carolina with an additional office in Greenville, South Carolina | Finance |
| Somatocor Pharmaceuticals, Inc. | |
FASgen, Inc.
FASgen, Inc. Pharmaceuticals: MajorHealth Technology FASgen, Inc. develops novel molecule therapeutics. It provides therapeutic applications for cancer, infectious diseases, and metabolic disorders including obesity and diabetes. The company was founded by James D. Dick, Frank P. Kuhajda, Albert H. Owens, and Craig A. Townsend in 2000 and is headquartered in Baltimore, MD. | Health Technology |
FASgen LLC
FASgen LLC Pharmaceuticals: MajorHealth Technology FASgen LLC was engaged in pharmaceutical preparations. Its products are FAS-detect IHC and FAS-detect ELISA. The company was founded by Albert H. Owens Jr., Craig A. Townsend, James D. Dick and in 1999 and was headquartered in Baltimore, MD. | Health Technology |
Accuronix Therapeutics, Inc.
Accuronix Therapeutics, Inc. Medical SpecialtiesHealth Technology Accuronix Therapeutics, Inc. develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk. The firm also develops new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. Its s-2 receptors are expressed on the surface of rapidly proliferating cancer cells. The company was founded by William Hawkins and Robert Mach and is headquartered in St. Louis, MO. | Health Technology |
